Cargando…

Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers

Breast cancer (BC) prognosis in BRCA1 and BRCA2 mutation carriers has been reported contradictorily, and the significance of variables influencing prognosis in sporadic BC is not established in BC patients with hereditary BRCA1/BRCA2 mutations. In this retrospective cohort study, we analyzed the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Vocka, Michal, Zimovjanova, Martina, Bielcikova, Zuzana, Tesarova, Petra, Petruzelka, Lubos, Mateju, Martin, Krizova, Ludmila, Kotlas, Jaroslav, Soukupova, Jana, Janatova, Marketa, Zemankova, Petra, Kleiblova, Petra, Novotny, Jan, Konopasek, Bohuslav, Chodacka, Martina, Brychta, Milan, Sochor, Marek, Smejkalova-Musilova, Denisa, Cmejlova, Vlastimila, Kozevnikovova, Renata, Miskarova, Lenka, Argalacsova, Sona, Stolarova, Lenka, Lhotova, Klara, Borecka, Marianna, Kleibl, Zdenek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627684/
https://www.ncbi.nlm.nih.gov/pubmed/31141992
http://dx.doi.org/10.3390/cancers11060738
_version_ 1783434794636410880
author Vocka, Michal
Zimovjanova, Martina
Bielcikova, Zuzana
Tesarova, Petra
Petruzelka, Lubos
Mateju, Martin
Krizova, Ludmila
Kotlas, Jaroslav
Soukupova, Jana
Janatova, Marketa
Zemankova, Petra
Kleiblova, Petra
Novotny, Jan
Konopasek, Bohuslav
Chodacka, Martina
Brychta, Milan
Sochor, Marek
Smejkalova-Musilova, Denisa
Cmejlova, Vlastimila
Kozevnikovova, Renata
Miskarova, Lenka
Argalacsova, Sona
Stolarova, Lenka
Lhotova, Klara
Borecka, Marianna
Kleibl, Zdenek
author_facet Vocka, Michal
Zimovjanova, Martina
Bielcikova, Zuzana
Tesarova, Petra
Petruzelka, Lubos
Mateju, Martin
Krizova, Ludmila
Kotlas, Jaroslav
Soukupova, Jana
Janatova, Marketa
Zemankova, Petra
Kleiblova, Petra
Novotny, Jan
Konopasek, Bohuslav
Chodacka, Martina
Brychta, Milan
Sochor, Marek
Smejkalova-Musilova, Denisa
Cmejlova, Vlastimila
Kozevnikovova, Renata
Miskarova, Lenka
Argalacsova, Sona
Stolarova, Lenka
Lhotova, Klara
Borecka, Marianna
Kleibl, Zdenek
author_sort Vocka, Michal
collection PubMed
description Breast cancer (BC) prognosis in BRCA1 and BRCA2 mutation carriers has been reported contradictorily, and the significance of variables influencing prognosis in sporadic BC is not established in BC patients with hereditary BRCA1/BRCA2 mutations. In this retrospective cohort study, we analyzed the effect of clinicopathological characteristics on BC prognosis (disease-free survival [DFS] and disease-specific survival [DSS]) in hereditary BRCA1/BRCA2 mutation carriers. We enrolled 234 BRCA1/BRCA2 mutation carriers and 899 non-carriers, of whom 191 carriers and 680 non-carriers, with complete data, were available for survival analyses. We found that patients with ER-positive tumors developed disease recurrence 2.3-times more likely when they carried a BRCA1/BRCA2 mutation (23/60; 38.3% ER-positive carriers vs. 74/445; 16.6% ER-positive non-carriers; p < 0.001). ER-positive mutation carriers also had a 3.4-times higher risk of death due to BC compared with ER-positive non-carriers (13/60; 21.7% vs. 28/445; 6.3%; p < 0.001). Moreover, prognosis in ER-negative BRCA1/BRCA2 mutation carriers was comparable with that in ER-positive non-carriers. Our study demonstrates that ER-positivity worsens BC prognosis in BRCA1/BRCA2 mutation carriers, while prognosis for carriers with ER-negative tumors (including early-onset) is significantly better and comparable with that in ER-positive, older BC non-carriers. These observations indicate that BRCA1/BRCA2 mutation carriers with ER-positive BC represent high-risk patients.
format Online
Article
Text
id pubmed-6627684
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66276842019-07-23 Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers Vocka, Michal Zimovjanova, Martina Bielcikova, Zuzana Tesarova, Petra Petruzelka, Lubos Mateju, Martin Krizova, Ludmila Kotlas, Jaroslav Soukupova, Jana Janatova, Marketa Zemankova, Petra Kleiblova, Petra Novotny, Jan Konopasek, Bohuslav Chodacka, Martina Brychta, Milan Sochor, Marek Smejkalova-Musilova, Denisa Cmejlova, Vlastimila Kozevnikovova, Renata Miskarova, Lenka Argalacsova, Sona Stolarova, Lenka Lhotova, Klara Borecka, Marianna Kleibl, Zdenek Cancers (Basel) Article Breast cancer (BC) prognosis in BRCA1 and BRCA2 mutation carriers has been reported contradictorily, and the significance of variables influencing prognosis in sporadic BC is not established in BC patients with hereditary BRCA1/BRCA2 mutations. In this retrospective cohort study, we analyzed the effect of clinicopathological characteristics on BC prognosis (disease-free survival [DFS] and disease-specific survival [DSS]) in hereditary BRCA1/BRCA2 mutation carriers. We enrolled 234 BRCA1/BRCA2 mutation carriers and 899 non-carriers, of whom 191 carriers and 680 non-carriers, with complete data, were available for survival analyses. We found that patients with ER-positive tumors developed disease recurrence 2.3-times more likely when they carried a BRCA1/BRCA2 mutation (23/60; 38.3% ER-positive carriers vs. 74/445; 16.6% ER-positive non-carriers; p < 0.001). ER-positive mutation carriers also had a 3.4-times higher risk of death due to BC compared with ER-positive non-carriers (13/60; 21.7% vs. 28/445; 6.3%; p < 0.001). Moreover, prognosis in ER-negative BRCA1/BRCA2 mutation carriers was comparable with that in ER-positive non-carriers. Our study demonstrates that ER-positivity worsens BC prognosis in BRCA1/BRCA2 mutation carriers, while prognosis for carriers with ER-negative tumors (including early-onset) is significantly better and comparable with that in ER-positive, older BC non-carriers. These observations indicate that BRCA1/BRCA2 mutation carriers with ER-positive BC represent high-risk patients. MDPI 2019-05-28 /pmc/articles/PMC6627684/ /pubmed/31141992 http://dx.doi.org/10.3390/cancers11060738 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vocka, Michal
Zimovjanova, Martina
Bielcikova, Zuzana
Tesarova, Petra
Petruzelka, Lubos
Mateju, Martin
Krizova, Ludmila
Kotlas, Jaroslav
Soukupova, Jana
Janatova, Marketa
Zemankova, Petra
Kleiblova, Petra
Novotny, Jan
Konopasek, Bohuslav
Chodacka, Martina
Brychta, Milan
Sochor, Marek
Smejkalova-Musilova, Denisa
Cmejlova, Vlastimila
Kozevnikovova, Renata
Miskarova, Lenka
Argalacsova, Sona
Stolarova, Lenka
Lhotova, Klara
Borecka, Marianna
Kleibl, Zdenek
Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers
title Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers
title_full Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers
title_fullStr Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers
title_full_unstemmed Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers
title_short Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers
title_sort estrogen receptor status oppositely modifies breast cancer prognosis in brca1/brca2 mutation carriers versus non-carriers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627684/
https://www.ncbi.nlm.nih.gov/pubmed/31141992
http://dx.doi.org/10.3390/cancers11060738
work_keys_str_mv AT vockamichal estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT zimovjanovamartina estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT bielcikovazuzana estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT tesarovapetra estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT petruzelkalubos estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT matejumartin estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT krizovaludmila estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT kotlasjaroslav estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT soukupovajana estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT janatovamarketa estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT zemankovapetra estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT kleiblovapetra estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT novotnyjan estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT konopasekbohuslav estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT chodackamartina estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT brychtamilan estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT sochormarek estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT smejkalovamusilovadenisa estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT cmejlovavlastimila estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT kozevnikovovarenata estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT miskarovalenka estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT argalacsovasona estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT stolarovalenka estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT lhotovaklara estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT boreckamarianna estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers
AT kleiblzdenek estrogenreceptorstatusoppositelymodifiesbreastcancerprognosisinbrca1brca2mutationcarriersversusnoncarriers